A comparison of HIV‐1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype
- 20 August 2009
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 81 (10) , 1702-1709
Abstract
Concordance between the conventional HIV‐1 phenotypic drug resistance assay, PhenoSense™ (PS), and virco®TYPE HIV‐1 (vT), a drug resistance assay based on prediction of the phenotype, was investigated in a data set from the Stanford HIV Resistance database (hivdb). Depending on the drug, between 287 and 902 genotype–phenotype data pairs were available for comparisons. Test results (fold‐change values) in the two assays were highly correlated, with an overall mean correlation coefficient of 0.90 using single PS measurements. This coefficient rose to 0.94 when the vT results were compared to the mean of repeat PS measurements. These results are comparable with the corresponding correlation coefficients of 0.87 and 0.95, calculated using single measurements, and the mean of repeat measurements, respectively, as obtained in the Antivirogram® assay, the conventional HIV‐1 phenotypic drug resistance test on which vT is based. The proportion of resistance calls resulting in a “major” discordance (fully susceptible or maximal response by one assay but fully resistant or minimal response by the other) ranged from 0% to 8.1% for drugs for which two clinical test cut‐offs were available in both assays (didanosine, abacavir, tenofovir, saquinavir/r, fosamprenavir/r, and lopinavir/r), from 2.4% to 8.1% for the drugs for which two clinical test cut‐offs were available in the vT assay and one clinical test cut‐off in the PS assay (lamivudine, stavudine, indinavir/r, and atazanavir/r) and from 3.1% to 10.3% for drugs for which biological test cut‐offs were used (zidovudine, nevirapine, delavirdine, efavirenz, indinavir, ritonavir, nelfinavir, saquinavir, and fosamprenavir). Our analyses suggest that these assays provide comparable resistance information, which will be of value to physicians who may be presented with either or both types of test report in their practice. J. Med. Virol. 81:1702–1709, 2009.Keywords
This publication has 11 references indexed in Scilit:
- Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort DataJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modelingJournal of Virological Methods, 2007
- A Direct Comparison of Drug Susceptibility to HIV Type 1 from Antiretroviral Experienced Subjects as Assessed by the Antivirogram and PhenoSense Assays and by Seven Resistance AlgorithmsAIDS Research and Human Retroviruses, 2005
- Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility AssaysJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Antivirogram or Phenosense: A Comparison of their Reproducibility and an Analysis of their CorrelationAntiviral Therapy, 2004
- Weak Agreement between Antivirogram and PhenoSense Assays in Predicting Reduced Susceptibility to Antiretroviral DrugsJournal of Clinical Microbiology, 2004
- Natural Variation of Drug Susceptibility in Wild-Type Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2004
- Comparative Analysis of Two Commercial Phenotypic Assays for Drug Susceptibility Testing of Human Immunodeficiency Virus Type 1Journal of Clinical Microbiology, 2002
- World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testingAIDS, 2001
- A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2000